APA (7th ed.) Citation

V, N., JC, W., DJ, B., WY, C., DM, B., BA, M., . . . DYC, H. (2023). CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clinical genitourinary cancer, 21(1), 106.e1-106.e8. https://doi.org/10.1016/j.clgc.2022.07.008

Chicago Style (17th ed.) Citation

V, Navani, et al. "CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)." Clinical Genitourinary Cancer 21, no. 1 (2023): 106.e1-106.e8. https://doi.org/10.1016/j.clgc.2022.07.008.

MLA (9th ed.) Citation

V, Navani, et al. "CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)." Clinical Genitourinary Cancer, vol. 21, no. 1, 2023, pp. 106.e1-106.e8, https://doi.org/10.1016/j.clgc.2022.07.008.